Screener
Axsome Therapeutics AXSM Free cash flow
Free cash flow at other companies
Other financials
Where this comes from
Calculated from Axsome Therapeutics’s reported figures.
The source filing: Axsome Therapeutics’s 10-Q, filed May 4, 2026. Open the filing →
- Filed
- May 4, 2026, 5:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204274
FAQ
- What is Axsome Therapeutics's free cash flow?
- Axsome Therapeutics (AXSM) reported free cash flow of -$20.82M in Q1 2026.
- How has Axsome Therapeutics's free cash flow changed year-over-year?
- Axsome Therapeutics's free cash flow increased by 52.4% year-over-year, from -$43.71M to -$20.82M.
- What is the long-term trend for Axsome Therapeutics's free cash flow?
- Over 4 years (2021 to 2025), Axsome Therapeutics's free cash flow has grown at a -3.3% compound annual growth rate (CAGR), from -$108.53M to -$94.87M.
- What does free cash flow mean?
- Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.
Ask your AI about Axsome Therapeutics's free cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude